A phase I/II study of vaccination against minor histocompatibility antigens HA1 or HA2 after allogeneic stem cell transplantation for advanced haematological malignancies
Completed
- Conditions
- Haematological malignacies/leukaemic relapseCancerLeukaemia of unspecified cell type
- Registration Number
- ISRCTN11974092
- Lead Sponsor
- Hannover Medical School (Medizinischen Hochschule Hannover) (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
1. Advanced (high risk) leukaemia, after allogeneic haematopoietic stem cell transplantation (HSCT)
2. Disparity in HA1 or HA2 between donor and recipient
3. Informed consent
4. Aged 18 years or older, either sex
Exclusion Criteria
1. Acute or chronic graft-versus-host disease (GvHD) after allo-HSCT prior to immunisation
2. No informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Toxicity of immunisation<br>
- Secondary Outcome Measures
Name Time Method Prevention of relapse of leukaemia<br>